Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Claire, Le Bolay"'
Autor:
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 1, Pp 38-48 (2023)
Objective Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of
Externí odkaz:
https://doaj.org/article/fbfb7923863e4170999f2062f9b263dc
Autor:
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
Publikováno v:
ACR Open Rheumatology. 5:38-48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b9466da0aa9a79b3ec812df5812e5ab
https://doi.org/10.1002/acr2.11511
https://doi.org/10.1002/acr2.11511
Autor:
Daniel J, Wallace, Thomas, Dörner, David S, Pisetsky, Jorge, Sanchez-Guerrero, Anand C, Patel, Dana, Parsons-Rich, Claire, Le Bolay, Elise E, Drouin, Amy H, Kao, Hans, Guehring, Maria, Dall'Era
Publikováno v:
ACR open rheumatologyREFERENCES.
Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the efficacy and safety of evobrutinib in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8c914e887bef8a0fc2d37ee1efc59306
https://pubmed.ncbi.nlm.nih.gov/36530019
https://pubmed.ncbi.nlm.nih.gov/36530019